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Summary We have recently demonstrated an association between distant metastasis and the expression of the extracellular matrix
glycoprotein tenascin-C (Tn-C) in the invasion border of small axillary node-negative breast carcinomas. Our purpose was to assess the
relationship between the expression of Tn-C in the tumour invasion border and several histopathological and biological variables and to
compare their usefulness in predicting local and distant disease recurrences. The original patient group consisted of 143 women with axillary
node-negative breast cancer (one bilateral) treated with breast-conserving surgery and post-operative radiotherapy, and followed for a
median of 8 years. Because of the small number of recurrences an additional group of 15 similarly treated women with recurrent breast
cancer was also studied. The size of the tumour, its histology, including a possible intraductal component, and grade were re-evaluated. The
expression of erbB-2, p53, Ki-67 and Tn-C was evaluated by immunohistochemistry. Ploidy and S-phase fraction (SPF) were assessed by
flow cytometry. The only statistically significant prognostic factor for local recurrence was Tn-C expression in the invasion border. For
metastasis Ki-67 positivity, tumour size and Tn-C expression in the invasion border were statistically significant, but Ki-67 positivity was the
only independent prognostic factor. Tn-C expression in the invasion border was associated with a higher proliferation rate measured by Ki-67
and SPF, which is consistent with the suggested growth-promoting activity of Tn-C. Tn-C may be a useful marker in selecting patients for
adjuvant therapies to reduce the rate of both local and distant cancer recurrences.
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Tenascin-C (Tn-C) is an extracellular matrix glycoprotein
expressed transiently during embryogenesis, inflammation and
malignancy. It is variably present in the basement membrane
region of some adult epithelia and enhanced periductally next to
the basement membrane in intraductal carcinoma of the breast.
In infiltrating breast carcinoma Tn-C is expressed deeper in the
stroma (Ferguson et al, 1990; Howeedy et al, 1990). Cell culture
experiments suggest that Tn-C promotes cell growth by
augmenting the mitogenic effect of fibroblast growth factor and
that it is a prerequisite for epidermal growth factor-induced prolif-
eration (Sakakura et al, 1991; Jones et al, 1997). The most consis-
tent function of Tn-C seems to be that it decreases cell adhesion,
and therefore it has been speculated that Tn-C could promote
cancer cell invasion and metastasis (Sakakura et al, 1991; Yoshida
et al, 1995). In our recent study of axillary node-negative breast
cancer none ofthe tumours that did not express Tn-C in the stroma
(15/137) recurred. Eight out of the 11 tumours that developed
distant metastases within 5 years expressed Tn-C in the invasion
border (Jahkola et al, 1996). This association between the expres-
sion of Tn-C in the invasion area of small node-negative breast
cancers and distant metastases suggests a role in tumour spread.
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Breast cancer is a heterogeneous disease with different histo-
logical types and various biological features. Several parameters
of malignancy have been proposed as prognostic markers.
Theoretically, proliferation activity, genetic instability and markers
of tumour invasion capacity indicate a more aggressive disease. In
addition, rapid tumour growth also suggests a better response to
chemotherapy. Tumour size and axillary nodal status are still
important in predicting the outcome of breast cancer (Fisher et al,
1993). Metastatic tumour in axillary lymph nodes is the main crite-
rion for adjuvant treatment. However, 10-30% of axillary node-
negative patients develop distant metastases (EBCTCG, 1992). The
value of prognostic markers in axillary node-negative patients is
controversial and at present there is no agreement on any single
prognostic factor strong enough to select patients with node-nega-
tive breast cancer for adjuvant therapies (Mansour et al, 1994).
Breast-saving surgery is the treatment ofchoice when the tumour
is unifocal or confined to one quadrant, and a good aesthetic result
can be achieved. Post-operative radiotherapy reduces the risk of
local recurrence from 30% to 5% but does not improve survival
(EBCTCG, 1995; Fisher et al, 1995). Adjuvant systemic treatment
seems to prevent local recurrences (Haffty et al, 1991; Fisher et al,
1995). Patients with a local recurrence have an increased risk of
distant metastases (Whelan et al, 1994; Veronesi et al, 1995).
Moreover, it causes psychological morbidity and is usually treated
with mastectomy. There is a need to investigate optional or addi-
tional treatment modalities such as more effective systemic thera-
pies for women with a risk of local recurrence after limited surgery
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and irradiation (Gelber and Goldhirsch, 1994). Attempts have
also been made to find a subgroup of low-risk patients who do not
need radiotherapy (Clark et al, 1992; Veronesi et al, 1993; Liljegren
et al, 1994).
The aim of this work was to assess the relationship between the
expression of Tn-C in the tumour invasion border and several
histopathological and biological variables, and to compare their
usefulness in predicting local and distant disease recurrences. All
patients had undergone breast-conserving surgery and post-opera-
tive radiotherapy for node-negative breast cancer. Because the
number of recurrences was low we extended the study to recurrent
cases in another node-negative patient group treated in the same
way. Other parameters studied were age, histology of the tumour,
including a possible intraductal component, grade and size. An
immunohistochemical analysis oferbB-2 oncoprotein, p53-protein
and Ki-67 antigen, as well as ploidy and SPF determination by
flow-cytometry, was also performed.
PATIENTS AND METHODS
Original group of patients with breast-saving treatment
The original group consisted of 143 women with 144 node-
negative breast cancers (one bilateral) treated with breast-saving
surgery and axillary dissection at the Maria Hospital of Helsinki
(55 patients) and the Fourth Department of Surgery ofthe Helsinki
University Central Hospital (HUCH) (88 patients) in 1985-89.
Patients chosen for breast preservation presented preoperatively
with a clinically unifocal T NO (2 cm or less in diameter) tumour
without any cancer involvement at the resection margin found at
surgery. A clear resection margin was defined as 5 mm or more of
normal tissue measured histologically. Patients with narrower
margins were referred to re-resection or mastectomy.
Mastectomized patients were excluded from the study. All women
received post-operative radiotherapy (25 times 2 Gy) at the
Department ofOncology ofHUCH but no adjuvant chemotherapy
or hormonal therapy. The median follow-up time was 7.8 years,
range 5.4-11.4 years.
Additional breast cancer patients with recurrent
disease
In 1985-90 238 women with axillary node-negative breast cancer
(not already included in the original study) were treated similarly
and referred to the Department of Oncology of HUCH for radio-
therapy. Twenty-six (II%) of these had had a disease recurrence.
The rates of both local relapse (15/238, 6%) and distant metastasis
(16/238, 7%) at 5-year follow-up were comparable with those in
the original patient group, in which 4% had local recurrences and
8% distant metastases (Jahkola et al, 1996), suggesting an equal
standard of treatment. Paraffin-embedded specimens were avail-
able from 15 out of 26 tumours that recurred: seven local recur-
rences and 11 distant metastases, three patients having both. These
15 patients formed the new patient material. A comparison between
the patient groups with recurrent disease is presented in Table 1.
Tumour samples and pathological parameters
Sections of paraffin-embedded tissue specimens of the primary
tumours were reviewed and classified for histology, grade and
size. The extent ofthe intraductal component (ductal carcinoma in
Table 1 Characteristics of the relapsed cases of the original and new
patient groups
Original patients New patients P-value
Number of patients
Age of patients (years)
Median
Range
Distant metastasis
Local relapse
Breast
Axilla
Death of breast cancer
Histology
Ductal
Lobular
Others
Grade
1
2
3
Tumour size (mm)
Median
Range
DCIS +
DCIS -
EIC +
EIC -
Comedo-type DCIS
erbB-2 +
erbB-2 -
p53 +
p53 -
Ki-67 +
Ki-67 -
SPF high
SPF low
Aneuploid
Diploid
Expression of Tn-C in
invasion border
+
17 15
50.5
37.5-72.5
14
7
6
1
9
11
5
1
4
2
5
50.7
30.2-70.6
11
7
6
1
6
11
3
1
0.44a
0.68
>0.99
0.21
0.83b
5
3
3
15.0
1-25
7
10
16
2
13
2
13
11
3
3
11
13.5
7-23
4
11
14
Not performed
Not performed
3
10
10
4
10
3
4
11
10
2
9
2
0.67b
0.23a
0.47
>0.99
>0.99
0.64
0.69
0.24
>0.99
>0.99
aMann-Whitney U-test. bChi-square test. Other associations assessed by
Fisher's exact test.
situ; DCIS) was recorded. It was called extensive (EIC) if DCIS
comprised 25% or more of the tumour area encompassed by the
infiltrating tumour and DCIS was also present in the surrounding
tissue (Schnitt et al, 1987). The grade ofthe ductal carcinomas was
assessed according to Bloom and Richardson (1957). Tumour size
was measured in the histological sections and varied from 1 to
26 mm. The whole cross-section of the tumour was examined in
most cases. In prognostic studies with immunohistochemistry and
flow cytometry 6- 1 % of the samples could not be interpreted
because of technical failures or the fact that there was too little
malignant tissue left. The assessment of histopathological and
prognostic parameters was performed blinded to patient outcome.
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Immunohistochemical analysis of Tn-C, p53 protein,
Ki-67 antigen and erbB-2 protein
The monoclonal antibody 143BD7 against Tn-C was characterized
previously (Tiitta et al, 1992) and the detection and evaluation of
Tn-C in the invasion border of breast cancer by immunohisto-
chemistry has been described (Jahkola et al, 1996). In short,
tumours expressing Tn-C in the area of invasion with adjacent
normal tissue clearly visible were called Tn-C positive (Figure 1).
An invasion border ofthe tumour could be identified in 121 out of
the 159 tumours. In the rest, the invasion border was not included
in available specimens.
The monoclonal antibody to p53 protein (clone DO-7) and poly-
clonal anti-human Ki-67 were purchased from Dako (Glostrup,
Denmark). The optimal working dilutions were determined by
serial dilutions and was 1:300 for anti-p53 and 1:500 for anti-Ki-
67. Mouse monoclonal antibody E2-4001 raised against the intra-
cytoplasmic domain of the human erbB-2 antigen was obtained
from Molecular Oncology, Gaithersburg, MD, USA. A final
concentration of 6 jg ml (dilution 1:20) in the working solution
was used. p53 and Ki-67 primary antibodies were applied
overnight and erbB-2 antibody for 2 h at room temperature in
humidified chambers.
For immunostaining 4-jim-thick paraffin sections were cut and
mounted on 3-aminopropyl-triethoxy-silane (APES) (Sigma, St
Louis, MO, USA)-coated slides and treated in a microwave oven
as described previously (Victorzon, 1996).
Immunohistochemistry was performed using the anti-alkaline
phosphatase method as described (Jahkola et al, 1996) or the
avidin-biotin complex (ABC) immunoperoxidase technique
A
Figure 1 Expression of tenascin-C in the invasion border of infiltrating
ductal (A) and lobular (B) carcinoma of the breast
applying a commercial Elite ABC Kit (Vectastain, Vector
Laboratories, Burlingame, CA, USA), also described previously
(Victorzon, 1996).
The level of immunoreactivity of p53 and Ki-67 antigens was
expressed as the percentage of positive cancer cell nuclei.
Interpreting erbB-2 staining, all tumours with positive cell
membranes were scored positive. The p53 staining could be inter-
preted in 143/159 (90%), the Ki-67 staining in 141/159 (89%) and
the erbB-2 staining in 142/144 (99%) of the tumours. The anti-
erbB-2 antibody E2-4001 was no longer available when the new
material of 15 tumours was tested.
Ploidy and S-phase fraction determined by flow
cytometry
A modification of the method ofHedley et al (1983) was applied
(Hedley et al, 1983). In brief, two 50-jim-thick sections were
treated with 10 mg m[' proteinase K (Sigma) for 30 min at room
temperature. After filtration, the nuclei were treated with
RNAase (10 mg ml-') and stained with 25 jg ml' ethidium
bromide (Sigma) for at least 1 h. The DNA was determined by
flow cytometry (FACScan, Becton Dickinson, Mountain View,
CA, USA) using 15-mW excitation at 488 nm, and the total
emission above 560 nm was recorded. As the staining intensity
of fixed nuclei varies from one sample to another, no internal
standard was added. The lowest peak was assigned a DNA index
(DI) value of 1.00 and the DI values of other peaks were calcu-
lated with this as a reference. Therefore, possible hypodiploid
peaks were identified as diploid and the normal diploid peak as
hyperdiploid. The S-phase fraction (SPF) was calculated either
using the Cellfit program of the FACScan flow cytometer or
manually by a modified rectilinear method. If the automatic and
the manual methods gave different results, the lower SPF was
chosen. Usually, the manual method gave a lower result, because
it was only applied in those tumours in which it was felt that the
automatic method gave too high a SPF, e.g. when there was a
skewness to the right oftheGI peak. Ifthe sample contained less
than 15% aneuploid cells, the SPF was not calculated. At least
10 000 nuclei from each specimen were analysed. DNA ploidy
could be determined in 150/159 (94%) and SPF in 147/159 ofthe
tumours (92%).
Statistical methods
Chi-square test, Fisher's exact test and Mann-Whitney U-test were
used to test for association between variables and possible differ-
ences between patients with relapses in the original and in the new
patient groups. Metastasis-free survival (MFS) in the original
patient group according to each prognostic parameter was esti-
mated with the Kaplan-Meier method. The statistical significance
ofdifferences in outcome between patients with or without a prog-
nostic factor were calculated in the overall patient group (original
and additional patients combined) using the Cox proportional
hazard model to compute the hazard ratios of disease recurrence.
The statistical significance ofthe effect ofthe continuous variables
on disease recurrence was also tested with the Cox proportional
hazard model with the variable to be tested as the only covariate.
The multivariate analysis for metastasis was performed with the
Cox proportional hazard model entering the variables significant
in the univariate analysis. Two-sided P-values smaller than 0.05
were considered significant.
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Assignment of cut-off values
The median size of 13 mm was chosen to dichotomize the study
group. The median age at operation of all patients was 51.9 years.
For analysis the patients were divided into two groups, 50 years or
older or less than 50 years. The median SPF ofdiploid (2.4%) and
the median SPF ofaneuploid tumours (8.4%) were used as cut-off
values. A cut-off value of 20% positive nuclei was used for p53.
For Ki-67 5-15% positive expression in the nuclei was called
weak (+), 16-29% moderate (++) and 30% or more strongly posi-
tive (+++). Because there was no difference in metastasis between
Ki-67 +, ++ and +++ tumours, the classification was simplified by
combining these classes into one Ki-67-positive category of5% or
more of positive nuclei. Five per cent was also the median of
Ki-67 immunostaining. The cut-off values for prognostic factors
presented here were also used when analysing local recurrences
after breast-saving surgery.
RESULTS
Association of Tn-C in the invasion border with other
variables
The expression ofTn-C at the site ofinvasion was correlated with
a higher proliferation rate measured by the expression of Ki-67
antigen (2 5% positive nuclei) (P = 0.03) and a high SPF (P =
0.004). There was also an association with tumours notcomprising
an intraductal component (P = 0.04) (Table 2).
Rate and time of distant and local recurrences
The median follow-up of patients in the original study group was
7.8 years (range 5.7-11.4 years). Seven local relapses occurred
(5%), six in the ipsilateral breast and one in the axilla. In addition,
one patient had had an angiosarcoma in the treated breast. One
mastectomy was performed because of a painful post-radiation
Table 2 Association of Tn-C in invasion border with other prognostic factors
in axillary node-negative breast cancers
All tumours (%) Tn-C-positive Chi-square
invasion border P-value
(%)
All 121a 63 (52)
DCIS + 43 17 (40)
DCIS - 78 46 (59) 0.04
EIC+ 6 4 (67)
EIC- 115 59 (51) 0.46
erbB-2 + 7 3 (43)
erbB-2 - 103 51 (50) 0.73
p53+ 19 11 (58)
p53- 92 47 (51) 0.59
Ki-67 + 65 40 (62)
Ki-67- 45 18 (40) 0.03
SPF high 62 40 (65)
SPF low 51 19 (37) 0.004
Aneuploid 44 23 (52)
Diploid 72 37 (51) 0.93
aAn invasion border was present in 121 tumours out of the 159 in the archival
specimens available.
mastitis, and one mastectomy with immediate reconstruction
because of a poor cosmetic result. One cancer developed in the
contralateral breast. Distant metastasis occurred in 14 women
(10%), four ofwhom also had a local recurrence. The median time
oflocal recurrence was 2.9 years (range 1.3-6.9 years) and that of
distant metastasis 3.6 years (range 0.7-8.2 years) in the overall
patient group.
Metastasis-free survival in the original patient group
and prognostic factors
The 8-year metastasis-free survival (MFS) was 89% in the original
patients. Age, histology, grade, erbB-2, p53, SPF and ploidy did
not predict metastasis significantly in a univariate analysis. The
MFS in tumours 13 mm or smaller was 94%, and 86% in those
larger than 13 mm (P = 0.01). The MFS in Ki-67-positive tumours
was 84% and 96% in Ki-67-negative ones (P = 0.04). When Tn-C
was expressed in the invasion border the MFS was 84% compared
with 98% when there was no such expression (P = 0.03).
Prognostic factors of distant and local recurrence in
the overall patient group
In univariate analysis for metastasis, size (P = 0.05), SPF of
diploid tumours (P = 0.0001) and Ki-67 (P = 0.03) were signifi-
cant prognostic factors, whereas grade (P = 0.18), age (P = 0.51),
SPF of aneuploid tumours (P = 0.77) or of all tumours as a group
(P = 0.73) and p53 (P = 0.90) failed to show prognostic power as
continuous variables. The prognostic comparison of the catego-
rized variables is presented in Table 3. In addition, when the
diploid tumours were dichotomized to low and high SPF, the rela-
tive risk for metastasis in the high group was 3.16 (P = 0.05),
whereas there was no such difference in the aneuploid tumours.
Tn-C in the invasion border was statistically significant in
predicting metastasis, and for local recurrence it was the only
statistically significant prognostic factor (Table 3) with a hazard
ratio of 11.0, CI 1.4-85.1, P = 0.02.
The hazard ratio of metastasis in patients with a tumour larger
than 13 mm was 2.6, CI 1.1-5.9, P = 0.02, in those with Ki-67-
positive tumours 5.5, CI 1.6-18.7, P = 0.006, and in those
with tumours with Tn-C expression in the invasion border 3.4,
CI 1.1-10.4, P = 0.03 (Table 3). When these three variables were
introduced in a multivariate analysis, Ki-67 remained the only
independent prognostic factor for metastasis (Table 4).
DISCUSSION
Tn-C is produced by normal mesenchymal and epithelial cells as
well as some carcinoma cells (Lightner et al, 1994; Ishihara et al,
1995). Tn-C produced by carcinoma cells has been suggested to
facilitate the spreading ofthe carcinoma (Ishihara et al, 1995). Our
recent observation suggests that the expression of Tn-C at the
active site ofepithelial-stromal invasion indicates a more aggres-
sive disease (Jahkola et al, 1996). The present study shows that the
expression of Tn-C at the site of invasion is correlated with a
higher proliferation rate measured by flow cytometric analysis of
SPF and the immunohistochemical detection of Ki-67 antigen,
which gives further support to the active role of Tn-C in cancer
dissemination.
Tumour size is a well-known risk factor in node-negative breast
cancer for both distant and local recurrence. In a large study of
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Table 3 Distributions of prognostic factors and hazard ratios (HRs) for local recurrence and metastasis in 158 women with 159 axillary node-negative breast
cancers treated with breast-saving surgery and post-operative radiotherapy
Number of HR for local P-value HR for P-value
tumours recurrence metastasis
Age <50 years 56 1.0 1.0
Age .50 years 103 0.95 0.93 (NS) 0.68 0.34 (NS)
Histologya
Ductal 95 1.0 1.0
Lobular 35 1.0 1.0
Others 29 0.34 0.30 (NS) 0.37 0.18 (NS)
DCIS+ 57 1.0 1.0
DCIS - 102 0.77 0.63 (NS) 1.07 0.87 (NS)
EIC + 12 1.0 1.0
EIC- 147 1.04 0.97 (NS) 0.97 0.96 (NS)
Gradeb
1 51 1.0 1.0
2 34 1.0 0.66
3 26 2.86 0.30 (NS) 1.72 0.35 (NS)
Size >13 mm 66 1.0 1.0
Size <13 mm 91 0.80 0.69 (NS) 0.39 0.02
erbB-2 +c 11 1.0
erbB-2- 131 - 0.46 0.31 (NS)
p53 +d 22 1.0 1.0
p53 - 121 0.88 0.87 (NS) 0.58 0.29 (NS)
Ki-67 +e 80 1.0 1.0
Ki-67 - 61 0.69 0.55 (NS) 0.18 0.006
SPF high' 73 1.0 1.0
SPF low 72 1.37 0.58 (NS) 0.47 0.10 (NS)
Aneuploid 55 1.0 1.0
Diploid 95 1.82 0.37 (NS) 1.75 0.24 (NS)
Expression of Tn-C
in invasion
border
+ 63 1.0 1.0
58 0.09 0.02 0.30 0.03
aOthers: two papillary, one medullary, two mucinous, 14 tubular, ten tubulolobular. For comparison with 'others' ductal and lobular carcinomas were combined.
bGrade of 111 ductal and tubular carcinomas. cerbB-2 was stained only of the original patient material. Hazard ratio could not be computed because of no local
recurrences in the erbB-2 positive group. dp53 cut-off 20% of nuclei positive. eKi-67 cut-off 5% of nuclei positive. fSPF cut-off: median SPF of diploid tumours
2.4% and median of aneuploid tumours 8.4%.
Table 4 Multivariate analysis (Cox proportional hazard model) of the three
covariates statistically significant in univariate analysis of metastasis
Covariate P HR Cl (95%)
Ki-67 (±, 5% cut off) 0.03 10.0 1.3-77.2
Tumour size (continuous) 0.17 2.1 0.7-6.0
Tn-C in invasion border 0.34 1.8 0.56-5.8
1800patients who received locoregionaltherapy and had an 8-year
follow-up, tumour size was the strongest predictor for distant
recurrence. A high proliferation activity measured by the [3H]-
thymidine labelling index provided additional prognostic informa-
tion in intermediate size (1-2 cm) tumours. Cell proliferation was
the most significant predictor for locoregional relapse (Silvestrini
etal, 1995). As in ourstudy, SPF has been found to be a significant
prognostic factor of distant metastasis in diploid but not in aneu-
ploid tumours (Clark et al, 1989). A similar observation has been
made in soft-tissue sarcomas (Huuhtanen et al, 1996). The prog-
nostic value of immunohistochemically detected erbB-2 and p53
protein in early node-negative breast cancer is controversial
(Silvestrini et al, 1993; Ravdin and Chamness, 1995; Rosen et al,
1995). In this study those markers did not show prognostic power
for either local or distant recurrence.
Young age, tumour size, presence of carcinoma at the resection
margin and the presence of an extensive intraductal component
(EIC) are associated with a higher risk of local recurrence after
breast-conserving surgery (Boyages et al, 1990; Holland et al, 1990;
Borger et al, 1994; Gage et al, 1996; Schnitt et al, 1987). In the
present study EIC was present in only 8% ofthe tumours compared
with 20% in many of the previous studies, probably because the
selection criteria for breast conservation had been strict: only
tumours up to 2 cmin diameter(measuredclinically) andwith histo-
logically clear margins were accepted. In this selected material the
expression ofTn-C in the invasion border was the only marker that
predicted local recurrence. Our results suggest that patients with
carcinomas that do not express Tn-C in the invasion border do not
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need adjuvant treatments. On the other hand, patients with tumours
expressing Tn-C in the area of invasion have an increased risk of
developing both local and distant recurrences.
Small tumour size, low grade and old age have been proposed as
selection criteria for patients who might not benefit from radio-
therapy (Clark et al, 1992; Veronesi et al, 1993; Liljegren et al,
1994). However, in a highly selected group of 87 patients treated
with breast-conserving surgery without radiotherapy, the rate of
local recurrence rose to 16% when the median follow-up time was
56 months, therefore this prospective clinical trial was closed
(Schnitt et al, 1996). Because of the lack of reliable exclusion
criteria the importance of post-operative radiotherapy for all
patients has been reappraised (Morrow et al, 1995). The expres-
sion of Tn-C in the invasion border seems to be a biological
marker of a higher risk for local relapse, and the absence of Tn-C
might be used as an adjunct to define a group that could be left
without radiotherapy.
Our results suggest that more radical surgery should be consid-
ered, adjuvant treatment recommended and that follow-ups should
be more frequent and continued longer when Tn-C is expressed in
the tumour invasion border. Additional studies are needed to estab-
lish whether Tn-C expression in the invasion border can be used as
a criterion to select conservatively treated axillary node-negative
breast cancer patients for adjuvant chemotherapy or hormonal
therapy to reduce the risk ofboth local and distant disease spread.
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